Psychedelics Panel | Mental Healthcare Innovations Summit at Stanford Medicine
The psychedelics panel, facilitated by Lauren Packard, JD, brought together Jeffrey Becker, MD, Rosalind Watts, PhD, and Berra Yazar-Klosinski to discuss their research and experience in this field.
The Mental Healthcare Summit at Stanford Medicine brings together creators and action-oriented leaders across research, policy, government, funding, and mental health advocacy to build a cross-sector community and drive forward the powerful existing and emerging innovations in mental health to collectively reimagine what it is like to give and receive mental healthcare.
Jeffrey Becker, MD, trained at UCLA/NPI in both Medicine and Psychiatry with a focus on Neuropsychiatry and Functional Medicine. He is board-certified by the American Board of Psychiatry and Neurology as well as the American Board for Integrative and Holistic Medicine. He maintains clinical offices in Santa Barbara and Westwood and is affiliated with UCLA/NPI as Volunteer Clinical Faculty. He is a leading expert on Ketamine Therapy and is the Founder and CSO of Bexson Biomedical.
Rosalind Watts, MD, is a clinical psychologist and the founder of ACER Integration. Her contributions to the field of psychedelic therapy are numerous and include the development of the ACE model ‘Accept, Connect, Embody’, which has been used in clinical trials of both psilocybin and DMT, as well as the Watts Connectedness Scale, which is a psychometric tool for measuring outcomes of psychedelic therapy. Dr Watts is the former clinical lead on the Psilocybin for Depression trial at Imperial College London, the clinical track lead on the Synthesis Institute’s psychedelic practitioner training, and sits on the clinical advisory board of the Usona Institute.
Berra Yazar-Klosinski, PhD, is Chief Scientific Officer of the MAPS Public Benefit Corporation (MAPS PBC). Dr. Yazar-Klosinski is responsible for the development of strategic, catalytic, and capacity-building activities to facilitate research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. She has been actively involved in the various stages of nonclinical and clinical development of MDMA-assisted psychotherapy, LSD-assisted psychotherapy, cannabis, and ibogaine.
Lauren Packard, JD, works at the Tony Blair Institute for Global Change, where she focuses on science and innovation policy. Previously, she worked as a climate change litigator at the Center for Biological Diversity and for the California Department of Justice. She also serves on the board of the Robert Packard Center for ALS Research at Johns Hopkins.
Join the community
https://innovations.stanford.edu/summit/
Follow us on social
LinkedIn: https://www.linkedin.com/company/stanford-healthcare-innovation-lab/
Twitter: @StanfordHIL
Instagram: @StanfordSHIL
The psychedelics panel, facilitated by Lauren Packard, JD, brought together Jeffrey Becker, MD, Rosalind Watts, PhD, and Berra Yazar-Klosinski to discuss their research and experience in this field.
The Mental Healthcare Summit at Stanford Medicine brings together creators and action-oriented leaders across research, policy, government, funding, and mental health advocacy to build a cross-sector community and drive forward the powerful existing and emerging innovations in mental health to collectively reimagine what it is like to give and receive mental healthcare.
Jeffrey Becker, MD, trained at UCLA/NPI in both Medicine and Psychiatry with a focus on Neuropsychiatry and Functional Medicine. He is board-certified by the American Board of Psychiatry and Neurology as well as the American Board for Integrative and Holistic Medicine. He maintains clinical offices in Santa Barbara and Westwood and is affiliated with UCLA/NPI as Volunteer Clinical Faculty. He is a leading expert on Ketamine Therapy and is the Founder and CSO of Bexson Biomedical.
Rosalind Watts, MD, is a clinical psychologist and the founder of ACER Integration. Her contributions to the field of psychedelic therapy are numerous and include the development of the ACE model ‘Accept, Connect, Embody’, which has been used in clinical trials of both psilocybin and DMT, as well as the Watts Connectedness Scale, which is a psychometric tool for measuring outcomes of psychedelic therapy. Dr Watts is the former clinical lead on the Psilocybin for Depression trial at Imperial College London, the clinical track lead on the Synthesis Institute’s psychedelic practitioner training, and sits on the clinical advisory board of the Usona Institute.
Berra Yazar-Klosinski, PhD, is Chief Scientific Officer of the MAPS Public Benefit Corporation (MAPS PBC). Dr. Yazar-Klosinski is responsible for the development of strategic, catalytic, and capacity-building activities to facilitate research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. She has been actively involved in the various stages of nonclinical and clinical development of MDMA-assisted psychotherapy, LSD-assisted psychotherapy, cannabis, and ibogaine.
Lauren Packard, JD, works at the Tony Blair Institute for Global Change, where she focuses on science and innovation policy. Previously, she worked as a climate change litigator at the Center for Biological Diversity and for the California Department of Justice. She also serves on the board of the Robert Packard Center for ALS Research at Johns Hopkins.
Join the community
https://innovations.stanford.edu/summit/
Follow us on social
LinkedIn: https://www.linkedin.com/company/stanford-healthcare-innovation-lab/
Twitter: @StanfordHIL
Instagram: @StanfordSHIL
){kind=link}
Comments